Navigation Links
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

pt ranging up to the mid-twenty percent level on U.S. net sales of Intermezzo((R)). If Transcept elects to exercise its psychiatrist co-promotion option, Transcept will receive an additional double-digit royalty on the portion of U.S. net sales generated by psychiatrists. Under the agreement, Transcept can enter the market under the co-promotion option as early as the first anniversary of the commercial launch of Intermezzo((R) )by Purdue.

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, said, "This agreement is a transforming event for Transcept. Purdue has an established and growing primary care marketing and sales capability that we believe is ideally positioned to introduce Intermezzo((R)) to physicians. Purdue has a demonstrated track-record in the key disciplines needed to drive the awareness and acceptance of Intermezzo((R)), including successful experience marketing to national distributors, managed care organizations and primary care physicians. We believe that Intermezzo((R)) has the potential to occupy an important position in the substantial worldwide market for prescription sleep aids, and that our U.S. partnership with Purdue is a key step toward the commercial success of Intermezzo((R))."

Mr. Oclassen continued, "This agreement further increases our substantial cash reserves and aligns us with a powerful partner that will make a significant U.S. primary care sales and marketing investment. Our agreement with Purdue establishes the potential for a substantial Transcept revenue stream, and now enables us to focus increasing attention on prospective Intermezzo((R) )commercialization partners in other parts of the world. The increased resources Transcept receives from this collaboration will also support our continued product pipeline expansion efforts. Finally, our option to co-promote Intermezzo((R)) in the United States provides a
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Honors from the Rx Club, the Daveys, the GLOBALS, ,and ... ... (PRWEB) December 17, 2009 -- Chicago-based full-service healthcare communications ... advertising and marketing awards programs honoring exceptional creative and interactive ... Club presented G&A with 9 Awards of Excellence for the ...
(Date:12/16/2009)... scientists at the University of East Anglia (UEA) could ... or agricultural waste to generate clean electricity. , Published ... the National Academy of Sciences (PNAS), the researchers ... which some bacteria survive by ,breathing rocks,. , The ... of new microbe-based technologies such as fuel cells, or ...
(Date:12/16/2009)... -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), ... today announced that it will be launching the ... gene-expression profiling using its SmartChip(TM) Real-Time PCR System. ... comprehensive human microRNA panel of 885 microRNAs on ... offers customers the use of its proprietary SmartChip ...
(Date:12/16/2009)... Resources, one of the world,s leading research and ... that, according to responses from surveyed dermatologists, Centocor ... inhibitors) will capture 22 percent of the biologics ... moderate to severe psoriasis. Among these two agents, ... times as much patient share as briakinumab. ...
Breaking Biology Technology:Goble & Associates Creative Work Awarded at Advertising Industry Competitions 2Goble & Associates Creative Work Awarded at Advertising Industry Competitions 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 4'Rock-breathing' bacteria could generate electricity and clean up oil spills 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System 4In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
... PHILADELPHIA and LYON, France, Jan. 13 ... Penn Jersey Region of American Red Cross ... an agreement concerning the GMP clinical batches ... United States.(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/DC58023LOGO ) , (Logo: ...
... for Thursday, January 15th at 1:00PM PTNEW YORK, Jan. ... ) today announced that Michael S. Weiss, the Company,s ... at the J.P. Morgan 27th Annual Healthcare Conference being ... live on Thursday, January 15th at 1:00pm PT and ...
... Pharmaceuticals, Inc. (Nasdaq: ALSE ), today announced that ... agreement (the "Agreement") with Robert Gipson for the private placement ... a purchase price of $1.00 per share. The financing ... connection with the Agreement, Mr. Gipson agreed to the cancellation ...
Other Biology Technology:ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross 2Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4
(Date:12/16/2009)... Society has announced the winners of its student travel ... at the Moscone Convention Center in San Francisco, California, ... are selected based on scientific merit, with priority given ... conference. Each awardee receives a travel grant and ... 20. , The 2010 recipients of the Student Travel ...
(Date:12/16/2009)... get psyched up for contests, but when these rituals ... down before and during events, they could be causing ... for the symptoms of an injury, not the injury ... focuses on musculoskeletal health and sports medicine. "They may ... certain level, but pain occurs for a reason. It ...
(Date:12/16/2009)... 1 iQor, a global provider of business ... InfoWorld 100 Awards Top 100 IT project ... was the first submission for iQor. ,, "We are ... companies," said Vikas Kapoor, president and CEO of iQor. ... allowing us to work faster, smarter and with the ...
Breaking Biology News(10 mins):Biophysical Society announces winners of 2010 Student Travel Awards 2Biophysical Society announces winners of 2010 Student Travel Awards 3Biophysical Society announces winners of 2010 Student Travel Awards 4NSAIDs: Take 'em early and often when competing? Think again 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Studies examine how living conditions impact reproductive health 10141 1Studies examine how living conditions impact reproductive health 10141 2Temps Inc Acquires Medical Concepts Staffing Business From Analysts International Corporation 58423 1Temps Inc Acquires Medical Concepts Staffing Business From Analysts International Corporation 58423 2Heart Patients Benefit From At Home Care Study Finds 58421 1Heart Patients Benefit From At Home Care Study Finds 58421 2
... The December 2008 issue of BioScience includes a ... the Environment, coordinated by Louis J. Guillette, Jr., of the ... in the issue is as follows: , Meeting the ... John P. Incardona, and Matthew L. Rise. , As a ...
... summer for sports, fans. World records tumbled at the ... 200m world records, knocking tenths of a second off ... the last few decades, which made marathon runner Mark ... increase in population could account for these dramatic improvements. ...
... (SRC-2) a master regulator gene called a coactivator fast ... another day without food, they will die. , The severity ... W. O,Malley, chair of molecular and cellular biology at Baylor College ... that appears in the current issue of the journal Science ...
Other Biology News:BioScience tip sheet, December 2008 2100-meter sprint world record could go as low as 9.48 seconds 2Master gene plays key role in blood sugar levels 2
Human Cell Line Slides...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: